Page last updated: 2024-11-08

cantharidin and Condylomata Acuminata

cantharidin has been researched along with Condylomata Acuminata in 4 studies

Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.
cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.

Condylomata Acuminata: Sexually transmitted form of anogenital warty growth caused by the human papillomaviruses.

Research Excerpts

ExcerptRelevanceReference
" Adverse events experienced by the VP-102-treated participants were consistent with the pharmacodynamic action of cantharidin as a vesicant and were primarily mild to moderate in severity."7.01Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. ( Andres, J; Eads, K; Glover, DK; Guenthner, S; McFalda, W; Olivadoti, M; Rieger, J; Rosen, T; Rumney, P; Tate, M; Willson, C, 2021)
" Adverse events experienced by the VP-102-treated participants were consistent with the pharmacodynamic action of cantharidin as a vesicant and were primarily mild to moderate in severity."3.01Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. ( Andres, J; Eads, K; Glover, DK; Guenthner, S; McFalda, W; Olivadoti, M; Rieger, J; Rosen, T; Rumney, P; Tate, M; Willson, C, 2021)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19901 (25.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Guenthner, S1
McFalda, W1
Tate, M1
Eads, K1
Rieger, J1
Glover, DK1
Willson, C1
Rumney, P1
Rosen, T1
Andres, J1
Olivadoti, M1
Ruini, C1
Clanner-Engelshofen, BM1
Heppt, M1
Herzinger, T1
Sárdy, M1
Ruzicka, T1
French, LE1
Reinholz, M1
Recanati, MA1
Kramer, KJ1
Maggio, JJ1
Chao, CR1
Coskey, RJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts[NCT03981822]Phase 2105 participants (Actual)Interventional2019-06-25Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

"Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).~Number of warts present were recorded at each treatment visit as well as follow-up visits. For each post baseline treatment visit, the change in number of warts from baseline was calculated." (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionWarts (Mean)
Treatment Visit 2Treatment Visit 3Treatment Visit 4Study Day 84 EOT VisitFollow up Day 112Follow-up Visit Day 147 EOS
Part B Pooled With Part A VP-102 24-hour-5.3-6.3-7.1-7.4-8.1-7.9
Part B Pooled With Part A: Placebo 24-hour0.6-0.50.50.1-0.3-0.1
Part B Pooled With Part A: Placebo 6-hour-0.3-1.1-0.9-1.1-1.1-1.2
Part B Pooled With Part A: VP-102 6-hour-4.0-4.4-5.2-6.1-5.3-5.0

Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Change from baseline in total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Baseline to Study Day 84, Follow-up Visits at Days 112 and 147 (EOS)

,,,
Interventionmm^2 (Mean)
Study Day 84 (EOT)Follow-up Day 112Follow-up Visit Day 147 (EOS)
Part B Pooled With Part A VP-102 24-hour-72.87-82.79-68.78
Part B Pooled With Part A: Placebo 24-hour1.601.402.21
Part B Pooled With Part A: Placebo 6-hour-23.64-20.35-6.02
Part B Pooled With Part A: VP-102 6-hour-52.60-79.43-59.28

Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Percent Change from Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Percent change from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionWart percentage change from Baseline (Mean)
Treatment Visit 2Treatment Visit 3Treatment Visit 4Study Day 84 End of Treatment VisitFollow up Day 112Follow up Visit Day 147 End of Study
Part B Pooled With Part A VP-102 24-hour-58.5-69.3-77.3-77.1-79.2-79.6
Part B Pooled With Part A: Placebo 24-hour-2.6-17.80.6-5.5-14.2-12.9
Part B Pooled With Part A: Placebo 6-hour-6.2-8.9-5.1-1.61.9-6.0
Part B Pooled With Part A: VP-102 6-hour-41.4-49.0-65.8-79.7-68.2-42.5

Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Percent Change from baseline in the total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Baseline to Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

,,,
InterventionChange from baseline in % of wart area (Mean)
Study Day 84 (EOT)Follow-up Day 112Follow-up Day 147 (EOS)
Part B Pooled With Part A VP-102 24-hour-64.2-76.4-69.3
Part B Pooled With Part A: Placebo 24-hour-7.313.819.9
Part B Pooled With Part A: Placebo 6-hour-22.3-21.5-11.7
Part B Pooled With Part A: VP-102 6-hour-46.0-48.2-45.8

Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting 75% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2, (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionParticipants (Count of Participants)
Treatment Visit 2: Incidence of >=75% Clearance: YESTreatment Visit 3: Incidence of >=75% Clearance: YESTreatment Visit 4: Incidence of >=75% Clearance: YESStudy Day 84 EOT: Incidence of >=75% Clearance: YESF/U Visit Day 112: Incidence of >=75% Clearance: YESF/U Visit Day 147: Incidence of >=75% Clearance: YES
Part B Pooled With Part A VP-102 24-hour61412151313
Part B Pooled With Part A: Placebo 24-hour121232
Part B Pooled With Part A: Placebo 6-hour002234
Part B Pooled With Part A: VP-102 6-hour5811151310

Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting 90% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionParticipants (Count of Participants)
Treatment Visit 2: Incidence of >=90% Clearance: YESTreatment Visit 3: Incidence of >=90% Clearance: YESTreatment Visit 4: Incidence of >=90% Clearance: YESStudy Day 84 EOT: Incidence of >=90% Clearance: YESF/U Visit Day 112: Incidence of >=90% Clearance: YESF/U Visit Day 147: Incidence of >=90% Clearance: YES
Part B Pooled With Part A VP-102 24-hour4871199
Part B Pooled With Part A: Placebo 24-hour020022
Part B Pooled With Part A: Placebo 6-hour000223
Part B Pooled With Part A: VP-102 6-hour15714119

Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Clearance compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionParticipants (Count of Participants)
Treatment Visit 2: Yes, Complete ClearanceTreatment Visit 3: Yes, Complete ClearanceTreatment Visit 4: Yes, Complete ClearanceStudy Day 84 EOT: Yes, Complete ClearanceF/U Visit Day 112: Yes, Complete ClearanceF/U Visit Day 147: Yes, Complete Clearance
Part B Pooled With Part A VP-102 24-hour487988
Part B Pooled With Part A: Placebo 24-hour020022
Part B Pooled With Part A: Placebo 6-hour000123
Part B Pooled With Part A: VP-102 6-hour1461196

Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting reduction of ≥ 1 treatable wart from baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

InterventionParticipants (Count of Participants)
Treatment Visit 272493885Treatment Visit 272493886Treatment Visit 272493884Treatment Visit 272493887Treatment Visit 372493884Treatment Visit 372493885Treatment Visit 372493886Treatment Visit 372493887Treatment Visit 472493884Treatment Visit 472493885Treatment Visit 472493886Treatment Visit 472493887Study Day 84 EOT Visit72493884Study Day 84 EOT Visit72493885Study Day 84 EOT Visit72493886Study Day 84 EOT Visit72493887F/U Visit Day 11272493884F/U Visit Day 11272493885F/U Visit Day 11272493886F/U Visit Day 11272493887F/U Visit Day 147 EOS72493884F/U Visit Day 147 EOS72493885F/U Visit Day 147 EOS72493886F/U Visit Day 147 EOS72493887
NoYes - at least 1 wart reduction from Baseline
Part B Pooled With Part A: VP-102 6-hour22
Part B Pooled With Part A: Placebo 6-hour6
Part B Pooled With Part A VP-102 24-hour23
Part B Pooled With Part A: Placebo 24-hour6
Part B Pooled With Part A: VP-102 6-hour8
Part B Pooled With Part A: Placebo 6-hour18
Part B Pooled With Part A VP-102 24-hour4
Part B Pooled With Part A: Placebo 24-hour12
Part B Pooled With Part A: VP-102 6-hour20
Part B Pooled With Part A VP-102 24-hour21
Part B Pooled With Part A: Placebo 24-hour7
Part B Pooled With Part A: VP-102 6-hour10
Part B Pooled With Part A VP-102 24-hour6
Part B Pooled With Part A: Placebo 24-hour11
Part B Pooled With Part A: VP-102 6-hour23
Part B Pooled With Part A VP-102 24-hour17
Part B Pooled With Part A: Placebo 24-hour4
Part B Pooled With Part A: VP-102 6-hour7
Part B Pooled With Part A VP-102 24-hour10
Part B Pooled With Part A: Placebo 24-hour14
Part B Pooled With Part A: VP-102 6-hour19
Part B Pooled With Part A: Placebo 6-hour9
Part B Pooled With Part A: VP-102 6-hour11
Part B Pooled With Part A: Placebo 6-hour15
Part B Pooled With Part A VP-102 24-hour9
Part B Pooled With Part A: Placebo 6-hour10
Part B Pooled With Part A VP-102 24-hour18
Part B Pooled With Part A: Placebo 6-hour14
Part B Pooled With Part A: VP-102 6-hour13
Part B Pooled With Part A: Placebo 6-hour8
Part B Pooled With Part A VP-102 24-hour19
Part B Pooled With Part A: Placebo 24-hour5
Part B Pooled With Part A: VP-102 6-hour17
Part B Pooled With Part A: Placebo 6-hour16
Part B Pooled With Part A VP-102 24-hour8
Part B Pooled With Part A: Placebo 24-hour13

Reviews

1 review available for cantharidin and Condylomata Acuminata

ArticleYear
What's new about warts.
    Cutis, 1976, Volume: 18, Issue:4

    Topics: Antibodies, Viral; Cantharidin; Child; Condylomata Acuminata; Dinitrochlorobenzene; Glutaral; Humans

1976

Trials

2 trials available for cantharidin and Condylomata Acuminata

ArticleYear
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.
    American journal of clinical dermatology, 2021, Volume: 22, Issue:6

    Topics: Administration, Cutaneous; Adult; Cantharidin; Condylomata Acuminata; Double-Blind Method; Drug Admi

2021
Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial.
    Clinical and experimental obstetrics & gynecology, 2018, Volume: 45, Issue:3

    Topics: Adult; Cantharidin; Condylomata Acuminata; Female; Humans; Irritants; Male; Papillomaviridae; Pilot

2018

Other Studies

1 other study available for cantharidin and Condylomata Acuminata

ArticleYear
Cantharidin as an Alternative Treatment for Genital Warts: A Case Monitored With Optical Coherence Tomography.
    Acta dermato-venereologica, 2020, Sep-08, Volume: 100, Issue:16

    Topics: Cantharidin; Condylomata Acuminata; Humans; Papillomaviridae; Tomography, Optical Coherence; Warts

2020